Drug Approval | October 03, 2022
Lupin gets EIR from USFDA for its Ankleshwar facility
The inspection of the facility was conducted from August 16-19, 2022.
The inspection of the facility was conducted from August 16-19, 2022.
The plant is expected to start commercial operations from Q4FY24
The facility has the capacity to produce one crore doses per day
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
The company is one of the most profitable companies manufacturing speciality chemicals in India
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)